Illumina, Inc. (NASDAQ:ILMN) was downgraded by Vetr from a “buy” rating to a “hold” rating in a report issued on Thursday. They currently have a $209.78 price target on the life sciences company’s stock. Vetr‘s price target would suggest a potential upside of 2.60% from the stock’s previous close.

Other equities analysts also recently issued reports about the company. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $195.00 price target for the company in a report on Thursday, July 27th. Canaccord Genuity upgraded Illumina from a “hold” rating to a “buy” rating and raised their price target for the company from $170.00 to $215.00 in a report on Monday, August 7th. First Analysis upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price target for the company in a report on Wednesday, August 2nd. Barclays PLC restated an “equal weight” rating and set a $150.00 price target on shares of Illumina in a report on Wednesday, August 9th. Finally, BidaskClub upgraded Illumina from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $177.01.

Illumina (ILMN) traded up 2.36% during mid-day trading on Thursday, hitting $204.46. 1,387,386 shares of the stock traded hands. The firm’s 50-day moving average is $186.97 and its 200 day moving average is $177.03. Illumina has a 52-week low of $119.37 and a 52-week high of $205.21. The firm has a market cap of $29.85 billion, a P/E ratio of 41.02 and a beta of 0.83.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm had revenue of $662 million during the quarter, compared to the consensus estimate of $642.38 million. During the same period last year, the company earned $0.86 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. Equities analysts predict that Illumina will post $3.65 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Vetr Inc. Lowers Illumina, Inc. (ILMN) to Hold” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/01/vetr-inc-lowers-illumina-inc-ilmn-to-hold.html.

In other news, Director Jay T. Flatley sold 22,540 shares of Illumina stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $195.21, for a total transaction of $4,400,033.40. Following the transaction, the director now directly owns 539,176 shares of the company’s stock, valued at approximately $105,252,546.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $184.75, for a total value of $26,788.75. Following the transaction, the senior vice president now directly owns 10,791 shares in the company, valued at $1,993,637.25. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 159,945 shares of company stock worth $29,365,458. Insiders own 1.60% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Bridge Advisors bought a new position in Illumina during the first quarter worth $207,000. Daiwa Securities Group Inc. boosted its position in Illumina by 5.1% in the first quarter. Daiwa Securities Group Inc. now owns 4,100 shares of the life sciences company’s stock worth $700,000 after buying an additional 200 shares during the last quarter. Tyers Asset Management LLC boosted its position in Illumina by 12.0% in the first quarter. Tyers Asset Management LLC now owns 2,544 shares of the life sciences company’s stock worth $434,000 after buying an additional 272 shares in the last quarter. Advisory Services Network LLC acquired a new position in Illumina during the first quarter worth approximately $117,000. Finally, Canada Pension Plan Investment Board boosted its position in Illumina by 80,307.7% in the first quarter. Canada Pension Plan Investment Board now owns 20,906 shares of the life sciences company’s stock worth $3,567,000 after buying an additional 20,880 shares in the last quarter. 93.32% of the stock is currently owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.